308 related articles for article (PubMed ID: 30008435)
1. Targeted overexpression of catalase to mitochondria does not prevent cardioskeletal myopathy in Barth syndrome.
Johnson JM; Ferrara PJ; Verkerke ARP; Coleman CB; Wentzler EJ; Neufer PD; Kew KA; de Castro Brás LE; Funai K
J Mol Cell Cardiol; 2018 Aug; 121():94-102. PubMed ID: 30008435
[TBL] [Abstract][Full Text] [Related]
2. Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy.
Zhu S; Chen Z; Zhu M; Shen Y; Leon LJ; Chi L; Spinozzi S; Tan C; Gu Y; Nguyen A; Zhou Y; Feng W; Vaz FM; Wang X; Gustafsson AB; Evans SM; Kunfu O; Fang X
Circ Heart Fail; 2021 Jun; 14(6):e008289. PubMed ID: 34129362
[TBL] [Abstract][Full Text] [Related]
3. Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation.
Greenwell AA; Gopal K; Altamimi TR; Saed CT; Wang F; Tabatabaei Dakhili SA; Ho KL; Zhang L; Eaton F; Kruger J; Al Batran R; Lopaschuk GD; Oudit GY; Ussher JR
Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2255-H2269. PubMed ID: 33929899
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency.
Soustek MS; Falk DJ; Mah CS; Toth MJ; Schlame M; Lewin AS; Byrne BJ
Hum Gene Ther; 2011 Jul; 22(7):865-71. PubMed ID: 21091282
[TBL] [Abstract][Full Text] [Related]
5. Cardiolipin deficiency in Barth syndrome is not associated with increased superoxide/H
Goncalves RLS; Schlame M; Bartelt A; Brand MD; Hotamışlıgil GS
FEBS Lett; 2021 Feb; 595(3):415-432. PubMed ID: 33112430
[TBL] [Abstract][Full Text] [Related]
6. Loss of Mitochondrial Ca
Bertero E; Nickel A; Kohlhaas M; Hohl M; Sequeira V; Brune C; Schwemmlein J; Abeßer M; Schuh K; Kutschka I; Carlein C; Münker K; Atighetchi S; Müller A; Kazakov A; Kappl R; von der Malsburg K; van der Laan M; Schiuma AF; Böhm M; Laufs U; Hoth M; Rehling P; Kuhn M; Dudek J; von der Malsburg A; Prates Roma L; Maack C
Circulation; 2021 Nov; 144(21):1694-1713. PubMed ID: 34648376
[TBL] [Abstract][Full Text] [Related]
7. Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.
Le CH; Benage LG; Specht KS; Li Puma LC; Mulligan CM; Heuberger AL; Prenni JE; Claypool SM; Chatfield KC; Sparagna GC; Chicco AJ
J Biol Chem; 2020 Aug; 295(35):12485-12497. PubMed ID: 32665401
[TBL] [Abstract][Full Text] [Related]
8. Endurance training ameliorates complex 3 deficiency in a mouse model of Barth syndrome.
Soustek MS; Baligand C; Falk DJ; Walter GA; Lewin AS; Byrne BJ
J Inherit Metab Dis; 2015 Sep; 38(5):915-22. PubMed ID: 25860817
[TBL] [Abstract][Full Text] [Related]
9. Barth Syndrome Cardiomyopathy: An Update.
Pang J; Bao Y; Mitchell-Silbaugh K; Veevers J; Fang X
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456462
[TBL] [Abstract][Full Text] [Related]
10. AAV-Mediated TAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome.
Suzuki-Hatano S; Saha M; Rizzo SA; Witko RL; Gosiker BJ; Ramanathan M; Soustek MS; Jones MD; Kang PB; Byrne BJ; Cade WT; Pacak CA
Hum Gene Ther; 2019 Feb; 30(2):139-154. PubMed ID: 30070157
[TBL] [Abstract][Full Text] [Related]
11. The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.
Huang Y; Powers C; Moore V; Schafer C; Ren M; Phoon CK; James JF; Glukhov AV; Javadov S; Vaz FM; Jefferies JL; Strauss AW; Khuchua Z
Orphanet J Rare Dis; 2017 Mar; 12(1):49. PubMed ID: 28279226
[TBL] [Abstract][Full Text] [Related]
12. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
Sabbah HN
Heart Fail Rev; 2021 Mar; 26(2):237-253. PubMed ID: 33001359
[TBL] [Abstract][Full Text] [Related]
13. Barth syndrome.
Jefferies JL
Am J Med Genet C Semin Med Genet; 2013 Aug; 163C(3):198-205. PubMed ID: 23843353
[TBL] [Abstract][Full Text] [Related]
14. Increased Reactive Oxygen Species-Mediated Ca
Liu X; Wang S; Guo X; Li Y; Ogurlu R; Lu F; Prondzynski M; de la Serna Buzon S; Ma Q; Zhang D; Wang G; Cotton J; Guo Y; Xiao L; Milan DJ; Xu Y; Schlame M; Bezzerides VJ; Pu WT
Circulation; 2021 May; 143(19):1894-1911. PubMed ID: 33793303
[TBL] [Abstract][Full Text] [Related]
15. A critical appraisal of the tafazzin knockdown mouse model of Barth syndrome: what have we learned about pathogenesis and potential treatments?
Ren M; Miller PC; Schlame M; Phoon CKL
Am J Physiol Heart Circ Physiol; 2019 Dec; 317(6):H1183-H1193. PubMed ID: 31603701
[TBL] [Abstract][Full Text] [Related]
16. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies.
Wang G; McCain ML; Yang L; He A; Pasqualini FS; Agarwal A; Yuan H; Jiang D; Zhang D; Zangi L; Geva J; Roberts AE; Ma Q; Ding J; Chen J; Wang DZ; Li K; Wang J; Wanders RJ; Kulik W; Vaz FM; Laflamme MA; Murry CE; Chien KR; Kelley RI; Church GM; Parker KK; Pu WT
Nat Med; 2014 Jun; 20(6):616-23. PubMed ID: 24813252
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice.
Russo S; De Rasmo D; Signorile A; Corcelli A; Lobasso S
Sci Rep; 2022 Nov; 12(1):19847. PubMed ID: 36400945
[TBL] [Abstract][Full Text] [Related]
18. Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.
Lou W; Reynolds CA; Li Y; Liu J; Hüttemann M; Schlame M; Stevenson D; Strathdee D; Greenberg ML
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):857-865. PubMed ID: 29694924
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel mitochondrial localization signals in human Tafazzin, the cause of the inherited cardiomyopathic disorder Barth syndrome.
Dinca AA; Chien WM; Chin MT
J Mol Cell Cardiol; 2018 Jan; 114():83-92. PubMed ID: 29129703
[TBL] [Abstract][Full Text] [Related]
20. Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy.
Ikon N; Ryan RO
Lipids; 2017 Feb; 52(2):99-108. PubMed ID: 28070695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
